Literature DB >> 29471945

PCSK9 as a Positive Modulator of Platelet Activation.

Marina Camera, Laura Rossetti, Silvia S Barbieri, Ilaria Zanotti, Barbara Canciani, Daniela Trabattoni, Massimiliano Ruscica, Elena Tremoli, Nicola Ferri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29471945     DOI： 10.1016/j.jacc.2017.11.069

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  19 in total

Review 1.  Lipid-Lowering Therapy in Women of Childbearing Age: a Review and Stepwise Clinical Approach.

Authors:  Jelani K Grant; Sarah Snow; Michelle Kelsey; Jennifer Rymer; Anna E Schaffer; Manesh R Patel; Robert W McGarrah; Neha J Pagidipati; Nishant P Shah
Journal:  Curr Cardiol Rep       Date:  2022-07-29       Impact factor: 3.955

Review 2.  Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall.

Authors:  Sabina Ugovšek; Miran Šebeštjen
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

3.  Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.

Authors:  Vittoria Cammisotto; Francesco Baratta; Valentina Castellani; Simona Bartimoccia; Cristina Nocella; Laura D'Erasmo; Nicholas Cocomello; Cristina Barale; Roberto Scicali; Antonino Di Pino; Salvatore Piro; Maria Del Ben; Marcello Arca; Isabella Russo; Francesco Purrello; Roberto Carnevale; Francesco Violi; Daniele Pastori; Pasquale Pignatelli
Journal:  Int J Mol Sci       Date:  2021-07-03       Impact factor: 5.923

4.  PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation.

Authors:  Vittoria Cammisotto; Daniele Pastori; Cristina Nocella; Simona Bartimoccia; Valentina Castellani; Cinzia Marchese; Antonio Sili Scavalli; Evaristo Ettorre; Nicola Viceconte; Francesco Violi; Pasquale Pignatelli; Roberto Carnevale
Journal:  Antioxidants (Basel)       Date:  2020-04-02

5.  Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies.

Authors:  Nicola Ferri; Maria Francesca Grego; Alberto Corsini; Massimiliano Ruscica
Journal:  Eur Heart J Suppl       Date:  2020-03-23       Impact factor: 1.803

6.  PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation.

Authors:  Elena Dozio; Massimiliano Ruscica; Elena Vianello; Chiara Macchi; Clementina Sitzia; Gerd Schmitz; Lorenza Tacchini; Massimiliano M Corsi Romanelli
Journal:  Mediators Inflamm       Date:  2020-06-04       Impact factor: 4.711

Review 7.  Influence of Cardiometabolic Risk Factors on Platelet Function.

Authors:  Cristina Barale; Isabella Russo
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

Review 8.  PCSK9 Biology and Its Role in Atherothrombosis.

Authors:  Cristina Barale; Elena Melchionda; Alessandro Morotti; Isabella Russo
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923

9.  Non-hematopoietic deficiency of proprotein convertase subtilisin/kexin type 9 deficiency leads to more severe anemia in a murine model of sickle cell disease.

Authors:  J Venugopal; J Wang; C Guo; H Lu; Y E Chen; D T Eitzman
Journal:  Sci Rep       Date:  2020-10-05       Impact factor: 4.379

10.  Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study.

Authors:  Jia Peng; Ming-Ming Liu; Jing-Lu Jin; Ye-Xuan Cao; Yuan-Lin Guo; Na-Qiong Wu; Cheng-Gang Zhu; Qian Dong; Jing Sun; Rui-Xia Xu; Jian-Jun Li
Journal:  Cardiovasc Diabetol       Date:  2020-10-06       Impact factor: 8.949
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.